Australia is eagerly awaiting the arrival of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, https://giant-bikes-usa896033.itbloghub.com/312409/this-new-drug-retatrutide-australia-a-promising-hope-for-obesity-treatment